Position in SYRE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,585,830
+$102,918 QoQ
Shares Held
71,091
-33.1% QoQ
Ownership
0.082%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 1%
Shared 0%
None 99%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MERCER GLOBAL ADVISORS INC /ADV holds $216,411,298 across 109 Biotechnology names. SYRE ranks #10 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
831,428 | $69,981,294 | |
| 2 | ORKA |
Oruka Therapeutics, Inc.
|
802,470 | $39,361,153 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
20,053 | $15,493,749 | |
| 4 | CAPR |
Capricor Therapeutics, Inc.
|
402,999 | $12,251,169 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
22,762 | $10,164,143 | |
| 6 | INCY |
Incyte Corp
|
93,266 | $8,778,195 | |
| 7 | ORMP |
Oramed Pharmaceuticals Inc.
|
1,910,540 | $6,495,836 | |
| 8 | EXEL |
Exelixis, Inc.
|
136,747 | $5,865,078 |
All Filings in SYRE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,585,830 | 71,091 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,482,912 | 106,316 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $1,787,688 | 106,664 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,588,945 | 106,142 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||